株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

小細胞肺癌:パイプライン分析

Small-Cell Lung Cancer - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 229729
出版日 ページ情報 英文 665 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.05円で換算しております。
Back to Top
小細胞肺癌:パイプライン分析 Small-Cell Lung Cancer - Pipeline Review, H1 2017
出版日: 2017年06月13日 ページ情報: 英文 665 Pages
概要

小細胞肺癌(SCLC)は、急速に進行する肺癌のタイプです。非小細胞肺癌より、急速に広がります。肺癌の中では、最も進行性の強い形態です。通常、胸部の中心の呼吸管(気管支)に発症します。多くの場合、脳、肝臓、骨を含む、体内の他の部位に急速に転移します。血痰、胸痛、咳、食欲不振、体重減少、喘鳴などの症状が見られます。治療には、外科手術、放射線療法、化学療法などが含まれます。

当レポートでは、小細胞肺癌に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

小細胞肺癌の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • 4SC AG
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • AbbVie Inc.
  • Alchemia Limited
  • Amgen Inc.
  • Andarix Pharmaceuticals, Inc.
  • Aposense Ltd.
  • アステラス製薬
  • AstraZeneca Plc
  • AVEO Pharmaceuticals, Inc.
  • Bayer AG
  • BeiGene, Ltd.
  • BIND Therapeutics, Inc.
  • BioLineRx, Ltd.
  • Bionomics Limited
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • CellAct Pharma GmbH
  • Cellceutix Corporation
  • Cerulean Pharma, Inc.
  • Cornerstone Pharmaceuticals, Inc.
  • Critical Outcome Technologies Inc.
  • CytRx Corporation
  • Double Bond Pharmaceutical International AB ほか

治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9398IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Small-Cell Lung Cancer - Pipeline Review, H1 2017, provides an overview of the Small-Cell Lung Cancer (Oncology) pipeline landscape.

Small cell lung cancer (SCLC) is a fast-growing type of lung cancer. It spreads much more quickly than non-small cell lung cancer. SCLC is the most aggressive form of lung cancer. It usually starts in the breathing tubes (bronchi) in the center of the chest. These tumors often spread rapidly (metastasize) to other parts of the body, including the brain, liver, and bone. Symptoms of SCLC include bloody sputum, chest pain, cough, loss of appetite, weight loss and wheezing. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Small-Cell Lung Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Small-Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 10, 41, 33, 2, 32 and 5 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Small-Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Small-Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Small-Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Small-Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Small-Cell Lung Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Small-Cell Lung Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Small-Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Small-Cell Lung Cancer - Overview
  • Small-Cell Lung Cancer - Therapeutics Development
  • Small-Cell Lung Cancer - Therapeutics Assessment
  • Small-Cell Lung Cancer - Companies Involved in Therapeutics Development
  • Small-Cell Lung Cancer - Drug Profiles
  • Small-Cell Lung Cancer - Dormant Projects
  • Small-Cell Lung Cancer - Discontinued Products
  • Small-Cell Lung Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Small-Cell Lung Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Small-Cell Lung Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2017
  • Small-Cell Lung Cancer - Pipeline by AbbVie Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Advantagene Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Alchemia Ltd, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Amgen Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Aposense Ltd, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Aprea AB, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Astellas Pharma Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Astex Pharmaceuticals Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by AstraZeneca Plc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Bayer AG, H1 2017
  • Small-Cell Lung Cancer - Pipeline by BeiGene (Beijing) Co Ltd, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Beta Pharma Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by BioLineRx Ltd, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Bionomics Ltd, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Celgene Corp, H1 2017
  • Small-Cell Lung Cancer - Pipeline by CellAct Pharma GmbH, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Cellceutix Corp, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Celldex Therapeutics Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Cornerstone Pharmaceuticals Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by CytRx Corp, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Double Bond Pharmaceutical International AB, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Eli Lilly and Company, H1 2017
  • Small-Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Forty Seven Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by G1 Therapeutics Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Genzyme Corp, H1 2017
  • Small-Cell Lung Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Horizon Pharma Plc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Immunomedics Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Incyte Corp, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Johnson & Johnson, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Karyopharm Therapeutics Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Lindis Biotech GmbH, H1 2017
  • Small-Cell Lung Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by MedImmune LLC, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Merck & Co Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Merck KGaA, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Mirati Therapeutics Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by MolMed SpA, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Mologen AG, H1 2017
  • Small-Cell Lung Cancer - Pipeline by NanoSmart Pharmaceuticals Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Nektar Therapeutics, H1 2017
  • Small-Cell Lung Cancer - Pipeline by NewLink Genetics Corp, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Nippon Kayaku Co Ltd, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Novartis AG, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Oxford BioTherapeutics Ltd, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Pfizer Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Pharma Mar SA, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Polaris Pharmaceuticals Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Recombio SL, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Sunshine Biopharma Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Syros Pharmaceuticals Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Tarveda Therapeutics Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Tesaro Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
  • Small-Cell Lung Cancer - Pipeline by United Therapeutics Corp, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Verastem Inc, H1 2017
  • Small-Cell Lung Cancer - Pipeline by ViiV Healthcare Ltd, H1 2017
  • Small-Cell Lung Cancer - Pipeline by Xencor Inc, H1 2017
  • Small-Cell Lung Cancer - Dormant Projects, H1 2017
  • Small-Cell Lung Cancer - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Small-Cell Lung Cancer - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Small-Cell Lung Cancer - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Small-Cell Lung Cancer - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Small-Cell Lung Cancer - Discontinued Products, H1 2017
  • Small-Cell Lung Cancer - Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures

  • Number of Products under Development for Small-Cell Lung Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top